Spain's Grifols has agreed to buy North Carolina-based Talecris Biotherapeutics for $3.4 billion, it has been announced. The Madrid-based company is buying Talecris, which makes blood plasma drugs, as part of its strategy to expand its business in blood products. Grifols, which specializes in plasma protein therapies and is present in more than 90 countries, said on Monday it expected about $230 million in annual synergies from the deal, which is also expected to boost earnings from the first year.